In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria

被引：42

作者：

Aguilar-Ayala, Diana A. ^{[1
,2
]}

Cnockaert, Margo ^{[1
]}

Andre, Emmanuel ^{[3
]}

Andries, Koen ^{[4
]}

Gonzalez-Y-Merchand, Jorge A. ^{[2
]}

Vandamme, Peter ^{[1
]}

Carlos Palomino, Juan ^{[1
]}

Martin, Anandi ^{[1
,3
]}

机构：

[1] Univ Ghent, Lab Microbiol, Ghent, Belgium

[2] Inst Politecn Nacl, Dept Microbiol, Escuela Nacl Ciencias Biol, Mexico City, DF, Mexico

[3] Catholic Univ Louvain, Pole Med Microbiol, Inst Expt & Clin Res, Brussels, Belgium

[4] Janssen Res & Dev, Beerse, Belgium

来源：

JOURNAL OF MEDICAL MICROBIOLOGY | 2017年 / 66卷 / 08期

关键词：

resistance to bedaquiline; nontuberculous mycobacteria; atpE mutation; Mycobacterium flavescens; minimum inhibitory concentration; minimum bactericidal concentration; MICROTITER ASSAY PLATE; ATP SYNTHASE INHIBITOR; RESISTANT TUBERCULOSIS; GENUS MYCOBACTERIUM; INEXPENSIVE METHOD; DRUG; DISEASE; UPDATE;

D O I：

10.1099/jmm.0.000537

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Bedaquiline (BDQ) has been proven to be effective in the treatment of multidrug-resistant tuberculosis. We hypothesized that BDQ could be a potential agent to treat nontuberculous mycobacterial (NTM) infection. The objective of this study was to evaluate the in vitro activity of BDQ against rapidly growing mycobacteria by assessing the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) against 18 NTM strains. For MIC determination we performed the resazurin microtitre assay broth dilution, and for the MBC the c.f.u. was determined. BDQ exhibited a strong inhibitory effect against most NTM tested; however, for some NTM strains the MBC was significantly higher than the MIC. A new finding is that Mycobacterium flavescens has a mutation in the gene atpE associated with natural resistance to BDQ. These preliminary promising results demonstrate that BDQ could be potentially useful for the treatment of NTM.

引用

页码：1140 / 1143

页数：4

共 19 条

[1] Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease [J].

Alexander, David C. ;

Vasireddy, Ravikiran ;

Vasireddy, Sruthi ;

Philley, Julie V. ;

Brown-Elliott, Barbara A. ;

Perry, Benjamin J. ;

Griffith, David E. ;

Benwill, Jeana L. ;

Cameron, Andrew D. S. ;

Wallace, Richard J., Jr. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2017, 55 (02) :574-584

[2] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].

Andries, K ;

Verhasselt, P ;

Guillemont, J ;

Göhlmann, HWH ;

Neefs, JM ;

Winkler, H ;

Van Gestel, J ;

Timmerman, P ;

Zhu, M ;

Lee, E ;

Williams, P ;

de Chaffoy, D ;

Huitric, E ;

Hoffner, S ;

Cambau, E ;

Truffot-Pernot, C ;

Lounis, N ;

Jarlier, V .

SCIENCE, 2005, 307 (5707) :223-227

[3] Current treatment of nontuberculous mycobacteriosis: an update [J].

Esteban, Jaime ;

Garcia-Pedrazuela, Maria ;

Carmen Munoz-Egea, Maria ;

Alcaide, Fernando .

EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (07) :967-986

[4] Multidrug-resistant tuberculosis around the world: what progress has been made? [J].

Falzon, Dennis ;

Mirzayev, Fuad ;

Wares, Fraser ;

Baena, Ines Garcia ;

Zignol, Matteo ;

Nguyen Linh ;

Weyer, Karin ;

Jaramillo, Ernesto ;

Floyd, Katherine ;

Raviglione, Mario .

EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (01) :150-160

[5] Global Tuberculosis Perspectives, Prospects, and Priorities [J].

Frieden, Thomas R. ;

Brudney, Karen F. ;

Harries, Anthony D. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (14) :1393-1394

[6] Rates and Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor [J].

Huitric, E. ;

Verhasselt, P. ;

Koul, A. ;

Andries, K. ;

Hoffner, S. ;

Andersson, D. I. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (03) :1022-1028

[7] In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor [J].

Huitric, Emma ;

Verhasselt, Peter ;

Andries, Koen ;

Hoffner, Sven E. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) :4202-4204

[8] Global tuberculosis drug development pipeline: the need and the reality [J].

Ma, Zhenkun ;

Lienhardt, Christian ;

McIlleron, Helen ;

Nunn, Andrew J. ;

Wang, Xiexiu .

LANCET, 2010, 375 (9731) :2100-2109

[9] Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs:: Rapid, simple, and inexpensive method [J].

Martin, A ;

Camacho, M ;

Portaels, F ;

Palomino, JC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3616-3619

[10] Nontuberculous Mycobacterial infections in Cystic Fibrosis [J].

Martiniano, Stacey L. ;

Nick, Jerry A. ;

Daley, Charles L. .

CLINICS IN CHEST MEDICINE, 2016, 37 (01) :83-+

← 1 2 →